Print  |  Close

A Long Term Follow-up Study of TScan TCR-T Products

Active: Yes
Cancer Type: Cancer-Related Syndrome
Leukemia
Myelodysplastic Syndromes (MDS) 		NCT ID: NCT06976736
Trial Phases: Protocol IDs: TSCAN-004 (primary)
NCI-2025-06747
Eligibility: 18 - 110 Years, Male and Female Study Type: Other
Study Sponsor: TScan Therapeutics
NCI Full Details: http://clinicaltrials.gov/show/NCT06976736

Summary

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have
previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study.
Participants will be monitored for 15 years from the date of TCR-T cell therapy
administration to assess long-term safety and efficacy.

Objectives

Participants will enroll in this LTFU study after completing the TSCAN-001 interventional
trial. No additional study drug will be administered; however, participants may receive
other cancer treatments as needed while being monitored for long-term safety.

Enrollment will occur after completion of the TSCAN-001 study, and participants will be
monitored for safety and efficacy over a 15 year period.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523


Doctors:
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.